FY2026 Earnings Forecast for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Issued By Leerink Partnrs

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of $1.42 for the year, down from their prior forecast of $2.31. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.63 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals' FY2027 earnings at $2.13 EPS and FY2028 earnings at $2.93 EPS.

ACAD has been the subject of several other research reports. Royal Bank of Canada decreased their price objective on shares of ACADIA Pharmaceuticals from $36.00 to $35.00 and set an "outperform" rating for the company in a research note on Wednesday, February 28th. Mizuho downgraded ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $39.00 to $25.00 in a research note on Tuesday, March 12th. Morgan Stanley reduced their price objective on ACADIA Pharmaceuticals from $40.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, March 13th. JPMorgan Chase & Co. lowered their target price on shares of ACADIA Pharmaceuticals from $29.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, March 25th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $42.00 price target on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $35.82.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock traded down $0.27 during trading hours on Friday, hitting $17.14. The company had a trading volume of 1,296,081 shares, compared to its average volume of 1,801,897. The company's 50-day moving average is $21.70 and its two-hundred day moving average is $23.91. The company has a market cap of $2.82 billion, a P/E ratio of -45.10 and a beta of 0.37. ACADIA Pharmaceuticals has a twelve month low of $16.85 and a twelve month high of $33.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.04). The business had revenue of $231.04 million for the quarter, compared to analyst estimates of $223.79 million. ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. ACADIA Pharmaceuticals's revenue was up 69.3% on a year-over-year basis. During the same period last year, the business posted ($0.26) EPS.

Insider Transactions at ACADIA Pharmaceuticals

In related news, CEO Stephen Davis sold 26,574 shares of the company's stock in a transaction on Monday, April 8th. The stock was sold at an average price of $17.87, for a total transaction of $474,877.38. Following the transaction, the chief executive officer now owns 144,267 shares of the company's stock, valued at $2,578,051.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Stephen Davis sold 26,574 shares of the company's stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $17.87, for a total value of $474,877.38. Following the sale, the chief executive officer now owns 144,267 shares in the company, valued at approximately $2,578,051.29. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Mark C. Schneyer sold 5,434 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $17.90, for a total transaction of $97,268.60. Following the transaction, the chief financial officer now owns 26,183 shares of the company's stock, valued at approximately $468,675.70. The disclosure for this sale can be found here. In the last three months, insiders sold 69,383 shares of company stock valued at $1,291,362. Corporate insiders own 27.50% of the company's stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Qube Research & Technologies Ltd increased its holdings in shares of ACADIA Pharmaceuticals by 757.2% during the 3rd quarter. Qube Research & Technologies Ltd now owns 212,919 shares of the biopharmaceutical company's stock worth $4,437,000 after buying an additional 188,080 shares during the last quarter. RTW Investments LP grew its holdings in shares of ACADIA Pharmaceuticals by 18.3% during the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company's stock worth $241,255,000 after purchasing an additional 1,793,288 shares during the period. Charles Schwab Investment Management Inc. increased its position in ACADIA Pharmaceuticals by 9.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,073,093 shares of the biopharmaceutical company's stock worth $22,363,000 after purchasing an additional 91,641 shares in the last quarter. Northern Trust Corp raised its holdings in ACADIA Pharmaceuticals by 4.9% in the third quarter. Northern Trust Corp now owns 1,220,677 shares of the biopharmaceutical company's stock valued at $25,439,000 after buying an additional 57,555 shares during the period. Finally, SG Americas Securities LLC lifted its position in ACADIA Pharmaceuticals by 1,284.6% during the third quarter. SG Americas Securities LLC now owns 72,455 shares of the biopharmaceutical company's stock valued at $1,510,000 after buying an additional 67,222 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.